Success Metrics

Active Trials
3(75%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Terminated(1)

Detailed Status

Active, not recruiting2
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (50.0%)
N/A1 (50.0%)

Trials by Status

active_not_recruiting250%
recruiting125%
withdrawn125%

Recent Activity

3 active trials
Showing 4 of 4
active_not_recruitingnot_applicable

Trans-RosaLEE Study: a Biomarker-directed, Translational Study

NCT05529862
active_not_recruitingphase_2

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

NCT06784947
recruiting

Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer

NCT06358625
withdrawn

Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies

NCT03877250

Clinical Trials (4)

Showing 4 of 4 trials
NCT05529862Not Applicable

Trans-RosaLEE Study: a Biomarker-directed, Translational Study

Active Not Recruiting
NCT06784947Phase 2

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

Active Not Recruiting
NCT06358625

Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer

Recruiting
NCT03877250

Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
4